Chicago Partners Investment Group LLC Acquires New Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Chicago Partners Investment Group LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 7,156 shares of the biotechnology company’s stock, valued at approximately $247,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. FMR LLC increased its holdings in Exelixis by 6.1% in the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after purchasing an additional 140,568 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Exelixis by 124.0% in the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after buying an additional 991,494 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Exelixis by 6.1% in the 3rd quarter. Two Sigma Advisers LP now owns 1,702,590 shares of the biotechnology company’s stock valued at $44,182,000 after buying an additional 98,000 shares during the period. Systematic Financial Management LP lifted its stake in Exelixis by 7.1% during the 3rd quarter. Systematic Financial Management LP now owns 1,168,391 shares of the biotechnology company’s stock worth $30,320,000 after acquiring an additional 77,599 shares in the last quarter. Finally, Retirement Systems of Alabama boosted its holdings in Exelixis by 24.6% during the 3rd quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company’s stock valued at $23,653,000 after acquiring an additional 180,021 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $35.27, for a total transaction of $352,700.00. Following the completion of the sale, the executive vice president now owns 278,665 shares in the company, valued at $9,828,514.55. This represents a 3.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the transaction, the executive vice president now directly owns 486,059 shares in the company, valued at $17,823,783.53. The trade was a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 111,588 shares of company stock worth $3,981,864 in the last quarter. 2.85% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on EXEL shares. TD Cowen increased their price target on shares of Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Stephens reiterated an “equal weight” rating and set a $29.00 target price on shares of Exelixis in a report on Monday, January 27th. Royal Bank of Canada restated an “outperform” rating and issued a $34.00 price target on shares of Exelixis in a research note on Wednesday, October 30th. Oppenheimer cut Exelixis from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $41.00 to $33.00 in a research note on Friday, January 24th. Finally, Bank of America cut Exelixis from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $35.00 to $39.00 in a research note on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.06.

Exelixis Stock Performance

Shares of EXEL stock opened at $33.12 on Wednesday. The stock’s 50-day moving average is $34.54 and its two-hundred day moving average is $30.33. Exelixis, Inc. has a 1 year low of $20.01 and a 1 year high of $37.59. The firm has a market cap of $9.46 billion, a price-to-earnings ratio of 21.23, a PEG ratio of 0.72 and a beta of 0.53.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.